Quadruplet Isa-KRd Regimen Improves NGS-MRD Negativity in Transplant-Eligible Patients with Newly Diagnosed Multiple Myeloma By Ogkologos - April 20, 2026 259 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the EMN24 IsKia study Source RELATED ARTICLESMORE FROM AUTHOR Comprehensive Genomic Profiling with Subsequent Molecularly Guided Therapy Improves Outcomes Over Platinum-based Chemotherapy in Previously Untreated, Unfavourable CUP NCI and CRUK Take on Cancer’s Toughest Problems Tebentafusp Continues to Provide Long-Term OS Benefit in Previously Untreated Patients with Unresectable or Metastatic Uveal Melanoma MOST POPULAR Should CAR T Cells Be Used Earlier in People with Non-Hodgkin... January 13, 2022 How will new cancer medicines be approved in the future? December 2, 2021 Women at High Risk of Breast Cancer Find it Hard to... April 22, 2021 Ethnic Diversity and Disparities in Access to Genetic Testing Impact Prostate... November 28, 2022 Load more HOT NEWS Adding Palbociclib to Maintenance Anti-HER2 and Endocrine Therapies Improves PFS Over... Opinion: “There’s cause for optimism in 2021 and beyond” Foodie Friday: Pumpkin EVERYTHING! Camonsertib in Patients with Advanced Solid Tumours Harbouring Loss of Function...
